Speclipse, a Seoul, South Korea-based developer of laser spectroscopic and AI-based medical diagnosis technologies, raised $7.7M in funding.
The round was led by Signite Partners with participation from BNH Investment, Shinhan Capital, MiCo and MiCoBioMed.
The company intends to use the funds to accelerate growth, expand operations and its business reach.
Led by Sung Hyun Pyun, Speclipse provides a laser spectroscopic technique and artificial intelligence technology – originally used for tissue diagnostics – to blood analysis. The company’s laser spectroscopic technology overcomes the limitations of existing blood analysis technologies in that it can simultaneously detect small variances in various blood biomarkers. Speclipse also uses Al and deep learning technologies to process and analyze large amounts of blood spectroscopic data, thereby enabling the early diagnosis of gastric cancer and Alzheimer’s disease.